Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 898-904

  Echevarría, Iciar ^a   Barturen, Celia ^a   Renedo, María Jesús ^a   Trocóniz, Iñaki F ^a   Dios Viéitez, M Carmen ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; POLOXAMER;

ANIMAL TISSUE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY FUNCTION; MALE; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; MALE; MODELS, BIOLOGICAL; PARTICLE SIZE; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ULTRAVIOLET; SPLEEN; TISSUE DISTRIBUTION;

EID: 0034061048     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.898-904.2000     Document Type: Article

References (26)

1. Adler-Moore, J. P., G, Fuji, and M. A. Lee. 1993. In vitro and in vivo interactions of Ambisome with pathogenic fungi. J. Liposome Res. 3:151-156.
2. Akaike, H. 1974. A new look at the statistical model identification. IEEE Trans. Automat. Control 19:716-723.
3. Bartels, H., M. Böhmer, and C. Heierli. 1972. Serum Kreatinibestimmung ohne Enteiweissen. Clin. Chim. Acta 37:193-197.
4. Bhamra, R., A. Sa'ad, L. E. Bolcsak, A. S. Janoff, and C. E. Swenson. 1997. Behaviour of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 41:886-892.
5. Boswell, G. W., I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. 1998. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263-268.
6. Boxenbaum, H. G., S. Riegelman, and R. M. Elashoff. 1974. Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm. 2:123-148.
7. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531.
8. Chow, H. H., Y. Wu, and M. Mayersohn. 1995. Pharmacokinetics of amphotericin B in rats as a function of dose following constant-rate intravenous infusion. Biopharm. Drug Dispos. 16:461-473.
9. Cooke, J. 1994. Pharmacoeconomics of antifungal therapy. Bone Marrow Transplant. 14(Suppl. 5):S18-S20.
10. Echevarría, I., C. Barturen, M. J. Renedo, and M. C. Dios-Viéitez. 1998. High-performance liquid chromatographic determination of amphotericin B in plasma and tissue. Application to pharmacokinetic and tissue distribution studies in rats. J. Chromatogr. A 819:171-176.
11. Espuelas, M. S., P. Legrand, J. M. Irache, C. Gamazo, A. M. Orecchioni, J.-P. Devissaguet, and P. Ygartua. 1997. Poly(ε-caprolactone) nanospheres as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158: 19-27.
12. Espuelas, M. S., P. Legrand, M. Chéron, G. Barratt, F. Puisieux, J.-P. Devissaguet, and J. M. Irache. 1998. Interaction of amphotericin B with polymeric colloids. 1. A spectroscopic study. Colloid. Surf. B Biointerf. 11: 141-151.
13. Espuelas, M. S., P. Legrand, M. Chéron, G. Barratt, F. Puisieux, M. J. Renedo, J.-P. Devissaguet, and J. M. Irache. 1998. Interaction of amphotericin B with polymeric colloids. 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(ε caprolactone) nanospheres. Colloid. Surf. B Biointerf. 11:203-212.
14. Garrido, M. J., M. Vale, R. Calvo, and I. F. Trocóniz. 1999. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J. Pharmacol. Exp. Ther. 288:179-187.
15. Hillery, A. M. 1997. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev. 24:345-363.
16. Kreft, B., C. De Wit, R. Marre, and K. Sack. 1991. Experimental studies on the nephrotoxicity of amphotericin B in rats. J. Antimicrob. Chemother. 28: 271-281.
17. Lee, J. W., M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (Ambisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
18. Moghimi, S. M. 1995. Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Adv. Drug Deliv. Rev. 16:183-193.
19. Müllen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine viceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
20. Olsen, S. J., M. R. Swerdel, B. Blue, J. M. Clark, and D. P. Bonner. 1991. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:831-835.
21. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics. Concepts and applications, 3rd ed. The William & Wilkins Co., Media, Pa.
22. Schwarz, G. 1978. Estimating the dimension of a model. Ann. Stat. 6:461-468.
23. Tasset, C., V. Preat, A. Bernard, and M. Roland. 1992. Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats. Antimicrob. Agents Chemother. 36:1525-1531.
24. Wade, A., and P. J. Weller. 1994. Handbook of pharmaceutical excipients, p. 352. American Pharmaceutical Association, Washington, D.C.
25. Walsh, T. J., V. Yeldandi, M. Mcevoy, C. Gonzalez, S. Chanock, A. Freifeld, N. I. Seibel, P. O. Withcomb, P. Jarosinsky, G. Boswell, I. Bekersky, A. Alak, D. Buell, J. Barret, and W. Wilson. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar formulation of amphotericin B (Ambisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391-2398.
26. Wasan, K. M., A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. Wen-Lin Chou, and P. H. Pritchard. 1998. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152.